{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T07:40:02Z","timestamp":1765438802444},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,21]]},"DOI":"10.7759\/cureus.30549","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T14:23:05Z","timestamp":1666362185000},"source":"Crossref","is-referenced-by-count":1,"title":["Role of Statin in Reducing Cardiovascular Diseases in Human Immunodeficiency Virus (HIV) Patients: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Ahmed","family":"Abdelghafar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moiud","family":"Mohyeldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama S","family":"Haroon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feras O","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Alfardous Alazm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244675","article-title":"Cardiovascular risk and response to lipid lowering therapy in patients with HIV infection according to different recommendations","volume":"15","author":"Pawlos A","year":"2020","unstructured":"Pawlos A, Broncel M, Wlaz\u0142owska E, Jab\u0142onowska E, Gorzelak-Pabi\u015b P. Cardiovascular risk and response to lipid lowering therapy in patients with HIV infection according to different recommendations. PLoS One. 2020, 15:e0244675. 10.1371\/journal.pone.0244675","journal-title":"PLoS One"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.5551\/jat.25908","article-title":"Risk of hypercholesterolemia for cardiovascular disease and the population attributable fraction in a 24-year Japanese cohort study","volume":"22","author":"Sugiyama D","year":"2015","unstructured":"Sugiyama D, Okamura T, Watanabe M, et al.. Risk of hypercholesterolemia for cardiovascular disease and the population attributable fraction in a 24-year Japanese cohort study. J Atheroscler Thromb. 2015, 22:95-107. 10.5551\/jat.25908","journal-title":"J Atheroscler Thromb"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1179\/2295333714Y.0000000069","article-title":"Cardiovascular disease prevention","volume":"69","author":"Van Camp G","year":"2014","unstructured":"Van Camp G. Cardiovascular disease prevention. Acta Clin Belg. 2014, 69:407-411. 10.1179\/2295333714Y.0000000069","journal-title":"Acta Clin Belg"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010116","article-title":"Statins in adult patients with HIV: Protocol for a systematic review and network meta-analysis","volume":"97","author":"Roever L","year":"2018","unstructured":"Roever L, Resende ES, Diniz AL, et al.. Statins in adult patients with HIV: Protocol for a systematic review and network meta-analysis. Medicine (Baltimore). 2018, 97:e0116. 10.1097\/MD.0000000000010116","journal-title":"Medicine (Baltimore)"},{"key":"ref5","article-title":"HIV-related cardiovascular disease, statins, and the REPRIEVE Trial","volume":"23","author":"Gilbert JM","year":"2015","unstructured":"Gilbert JM, Fitch KV, Grinspoon SK. HIV-related cardiovascular disease, statins, and the REPRIEVE Trial. Top Antivir Med. 2015, 23:146-149.","journal-title":"Top Antivir Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.02.005","article-title":"Lipoprotein-associated phospholipase A2 and its relationship with markers of subclinical cardiovascular disease: a systematic review","volume":"11","author":"Younus A","year":"2017","unstructured":"Younus A, Humayun C, Ahmad R, et al.. Lipoprotein-associated phospholipase A2 and its relationship with markers of subclinical cardiovascular disease: a systematic review. J Clin Lipidol. 2017, 11:328-337. 10.1016\/j.jacl.2017.02.005","journal-title":"J Clin Lipidol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-019-1147-1","article-title":"Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis","volume":"19","author":"Gu Y","year":"2019","unstructured":"Gu Y, Yang X, Liang H, Li D. Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis. BMC Gastroenterol. 2019, 19:231. 10.1186\/s12876-019-1147-1","journal-title":"BMC Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle A","year":"2017","unstructured":"Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017, 120:229-243. 10.1161\/CIRCRESAHA.116.308537","journal-title":"Circ Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2018.101088","article-title":"Statin treatment, oxidative stress and inflammation in a Danish population","volume":"21","author":"S\u00f8rensen AL","year":"2019","unstructured":"S\u00f8rensen AL, Hasselbalch HC, Nielsen CH, Poulsen HE, Ellervik C. Statin treatment, oxidative stress and inflammation in a Danish population. Redox Biol. 2019, 21:101088. 10.1016\/j.redox.2018.101088","journal-title":"Redox Biol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1370\/afm.1641","article-title":"Cardiovascular risk and statin use in the United States","volume":"12","author":"Johansen ME","year":"2014","unstructured":"Johansen ME, Green LA, Sen A, Kircher S, Richardson CR. Cardiovascular risk and statin use in the United States. Ann Fam Med. 2014, 12:215-223. 10.1370\/afm.1641","journal-title":"Ann Fam Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker PM","year":"2005","unstructured":"Ridker PM, Cannon CP, Morrow D, et al.. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005, 352:20-28. 10.1056\/NEJMoa042378","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.107.147280","article-title":"Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2","volume":"27","author":"Saougos VG","year":"2007","unstructured":"Saougos VG, Tambaki AP, Kalogirou M, et al.. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol. 2007, 27:2236-2243. 10.1161\/ATVBAHA.107.147280","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.97.12.1129","article-title":"Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors","volume":"97","author":"Laufs U","year":"1998","unstructured":"Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998, 97:1129-1135. 10.1161\/01.cir.97.12.1129","journal-title":"Circulation"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(02)01884-3","article-title":"Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease","volume":"39","author":"Alber HF","year":"2002","unstructured":"Alber HF, Dulak J, Frick M, et al.. Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease. J Am Coll Cardiol. 2002, 39:1951-1955. 10.1016\/s0735-1097(02)01884-3","journal-title":"J Am Coll Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000025419.95769.f0","article-title":"Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy","volume":"106","author":"Cipollone F","year":"2002","unstructured":"Cipollone F, Mezzetti A, Porreca E, et al.. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation. 2002, 106:399-402. 10.1161\/01.cir.0000025419.95769.f0","journal-title":"Circulation"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2174\/1874613601711010045","article-title":"Cholesterol screening and statin prescription is low among HIV-infected patients on protease-inhibitor regimens in Botswana","volume":"11","author":"Mosepele M","year":"2017","unstructured":"Mosepele M, Letsatsi V, Mokgatlhe L, Hudson FP, Gross R. Cholesterol screening and statin prescription is low among HIV-infected patients on protease-inhibitor regimens in Botswana. Open AIDS J. 2017, 11:45-51. 10.2174\/1874613601711010045","journal-title":"Open AIDS J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232636","article-title":"Association between statin use, atherosclerosis, and mortality in HIV-infected adults","volume":"15","author":"Phan BA","year":"2020","unstructured":"Phan BA, Ma Y, Scherzer R, Deeks SG, Hsue PY. Association between statin use, atherosclerosis, and mortality in HIV-infected adults. PLoS One. 2020, 15:e0232636. 10.1371\/journal.pone.0232636","journal-title":"PLoS One"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2012.0015","article-title":"Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk","volume":"29","author":"Calza L","year":"2013","unstructured":"Calza L, Manfredi R, Colangeli V, et al.. Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk. AIDS Res Hum Retroviruses. 2013, 29:547-556. 10.1089\/aid.2012.0015","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcct.2019.08.011","article-title":"Individual coronary plaque changes on serial CT angiography: Within-patient heterogeneity, natural history, and statin effects in HIV","volume":"14","author":"Foldyna B","year":"2020","unstructured":"Foldyna B, Lo J, Mayrhofer T, Grinspoon SK, Hoffmann U, Lu MT. Individual coronary plaque changes on serial CT angiography: Within-patient heterogeneity, natural history, and statin effects in HIV. J Cardiovasc Comput Tomogr. 2020, 14:144-148. 10.1016\/j.jcct.2019.08.011","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2020.1823468","article-title":"Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in treated HIV-infected patients with metabolic syndrome","volume":"53","author":"Calza L","year":"2021","unstructured":"Calza L, Colangeli V, Borderi M, et al.. Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in treated HIV-infected patients with metabolic syndrome. Infect Dis (Lond). 2021, 53:81-88. 10.1080\/23744235.2020.1823468","journal-title":"Infect Dis (Lond)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(14)00032-0","article-title":"Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Lo J","year":"2015","unstructured":"Lo J, Lu MT, Ihenachor EJ, et al.. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV. 2015, 2:e52-e63. 10.1016\/S2352-3018(14)00032-0","journal-title":"Lancet HIV"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.12.050","article-title":"Intensive statin regimens for reducing risk of cardiovascular diseases among human immunodeficiency virus-infected population: a nation-wide longitudinal cohort study 2000-2011","volume":"230","author":"Ou HT","year":"2017","unstructured":"Ou HT, Chang KC, Li CY, Yang CY, Ko NY. Intensive statin regimens for reducing risk of cardiovascular diseases among human immunodeficiency virus-infected population: a nation-wide longitudinal cohort study 2000-2011. Int J Cardiol. 2017, 230:592-598. 10.1016\/j.ijcard.2016.12.050","journal-title":"Int J Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2014.0309","article-title":"Myocardial infarction, stroke, and mortality in cART-treated HIV patients on statins","volume":"29","author":"Krsak M","year":"2015","unstructured":"Krsak M, Kent DM, Terrin N, Holcroft C, Skinner SC, Wanke C. Myocardial infarction, stroke, and mortality in cART-treated HIV patients on statins. AIDS Patient Care STDS. 2015, 29:307-313. 10.1089\/apc.2014.0309","journal-title":"AIDS Patient Care STDS"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu012","article-title":"Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy","volume":"209","author":"Eckard AR","year":"2014","unstructured":"Eckard AR, Jiang Y, Debanne SM, Funderburg NT, McComsey GA. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis. 2014, 209:1156-1164. 10.1093\/infdis\/jiu012","journal-title":"J Infect Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2017.0304","article-title":"Evaluation of statin eligibility, prescribing practices, and therapeutic responses using ATP III, ACC\/AHA, and NLA dyslipidemia treatment guidelines in a large urban cohort of HIV-infected outpatients","volume":"32","author":"Levy ME","year":"2018","unstructured":"Levy ME, Greenberg AE, Magnus M, Younes N, Castel A. Evaluation of statin eligibility, prescribing practices, and therapeutic responses using ATP III, ACC\/AHA, and NLA dyslipidemia treatment guidelines in a large urban cohort of HIV-infected outpatients. AIDS Patient Care STDS. 2018, 32:58-69. 10.1089\/apc.2017.0304","journal-title":"AIDS Patient Care STDS"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3162-1","article-title":"Statin use and all-cause mortality in people living with HIV: a systematic review and meta-analysis","volume":"18","author":"Uthman OA","year":"2018","unstructured":"Uthman OA, Nduka C, Watson SI, et al.. Statin use and all-cause mortality in people living with HIV: a systematic review and meta-analysis. BMC Infect Dis. 2018, 18:258. 10.1186\/s12879-018-3162-1","journal-title":"BMC Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/81348-role-of-statin-in-reducing-cardiovascular-diseases-in-human-immunodeficiency-virus-hiv-patients-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:51:07Z","timestamp":1707508267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/81348-role-of-statin-in-reducing-cardiovascular-diseases-in-human-immunodeficiency-virus-hiv-patients-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.30549","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,21]]}}}